Celgene, BMS, Teva Can't Pause Cancer Drugs Antitrust Suit

Celgene, BMS, Teva Can’t Pause Cancer Drugs Antitrust Suit

Source Node: 2604245
By Bryan Koenig (April 21, 2023, 9:57 PM EDT) — A New Jersey federal magistrate judge refused Friday to pump the brakes on consolidated antitrust lawsuits accusing Celgene and parent Bristol-Myers Squibb of conspiring with generic drugmakers Teva and Natco to delay generic competition to blockbuster cancer treatments, preferring to get a move on with the years-old litigation….

Time Stamp:

More from Law 360